Evidence map›Paper›PMID 26790477›Full record

ArticleTissue engineering. Part A2016

Effects of Dexamethasone on Satellite Cells and Tissue Engineered Skeletal Muscle Units.

Brian C Syverud, Keith W VanDusen, Lisa M Larkin

Abstract read
In one paragraph

Article in Tissue engineering. Part A, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Skeletal Muscle Tissue Engineering: From Tissue Regeneration to Biorobotics.Cyborg and bionic systems (Washington, D.C.) · 2025
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Tart Cherry (Fruit ofMedicina (Kaunas, Lithuania) · 2021
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Brian C Syverud1 Department of Biomedical Engineering, University of Michigan , Ann Arbor, Michigan.
Keith W VanDusen2 Department of Molecular and Integrated Physiology, University of Michigan , Ann Arbor, Michigan.
Lisa M Larkin1 Department of Biomedical Engineering, University of Michigan , Ann Arbor, Michigan.
University of Michigan–Ann Arbor · US

Funding

Microfluidics in Biomedical Sciences Training ProgramT32EB005582 · NIBIB · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FAN, XUDONG · 2005 to 2020
$3.9M
Utilization of Engineered Skeletal Muscle Units to Repair Volumetric MuscleR01AR067744 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LARKIN, LISA M · 2015 to 2019
$2.3M
Utilization of Engineered Skeletal Muscle Units to Repair Volumetric Muscle LossR56AR054778 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LARKIN, LISA M · 2014 to 2014
$156k
NIAMS NIH HHS 2-R56-AR-054778-06-A1NIAMS NIH HHS R01 AR067744NIBIB NIH HHS T32 EB005582
6 · The paper itself

Abstract

Tissue engineered skeletal muscle has potential for application as a graft source for repairing soft tissue injuries, a model for testing pharmaceuticals, and a biomechanical actuator system for soft robots. However, engineered muscle to date has not produced forces comparable to native muscle, limiting its potential for repair and for use as an in vitro model for pharmaceutical testing. In this study, we examined the trophic effects of dexamethasone (DEX), a glucocorticoid that stimulates myoblast differentiation and fusion into myotubes, on our tissue engineered three-dimensional skeletal muscle units (SMUs). Using our established SMU fabrication protocol, muscle isolates were cultured with three experimental DEX concentrations (5, 10, and 25 nM) and compared to untreated controls. Following seeding onto a laminin-coated Sylgard substrate, the administration of DEX was initiated on day 0 or day 6 in growth medium or on day 9 after the switch to differentiation medium and was sustained until the completion of SMU fabrication. During this process, total cell proliferation was measured with a BrdU assay, and myogenesis and structural advancement of muscle cells were observed through immunostaining for MyoD, myogenin, desmin, and α-actinin. After SMU formation, isometric tetanic force production was measured to quantify function. The histological and functional assessment of the SMU showed that the administration of 10 nM DEX beginning on either day 0 or day 6 yielded optimal SMUs. These optimized SMUs exhibited formation of advanced sarcomeric structure and significant increases in myotube diameter and myotube fusion index, compared with untreated controls. Additionally, the optimized SMUs matured functionally, as indicated by a fivefold rise in force production. In conclusion, we have demonstrated that the addition of DEX to our process of engineering skeletal muscle tissue improves myogenesis, advances muscle structure, and increases force production in the resulting SMUs.

Indexed as

AnimalsCell DifferentiationCell FusionCell LineCell ProliferationDexamethasoneFemaleFibroblastsMiceMuscle DevelopmentMuscle Fibers, SkeletalRats, Inbred F344Satellite Cells, Skeletal MuscleTissue EngineeringDexamethasone

Identifiers

PMID26790477
PMCPMC4800275
OpenAlexW2276151161

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.